3-Hydroxyphencyclidine (3-HPC), a breakdown product of phencyclidine (PCP), is ever more attracting clinical scrutiny due to limited information suggesting unique pharmacological characteristics. Preliminary analyses indicate that 3-HPC may exhibit distinct impacts on the central structure, possibly contributing to some of the unexplained manifesta